About Stelios Papadopoulos
Stelios Papadopoulos is a director at Exelixis.
Form D filings name Stelios Papadopoulos as a director at Epikast.
Stelios Papadopoulos reports to the SEC as a director or major shareholder of 9 public companies, including Ovid Therapeutics (OVID), Regulus Therapeutics (RGLS) and Biogen (BIIB).
Stelios Papadopoulos first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Stelios Papadopoulos in the role, so the role may have started earlier or lasted longer.
EI
Exelixis, Inc.
Director
2006 – 2026 · Public company (EXEL)
OI
Ovid Therapeutics Inc.
Director
2025 – 2026 · Public company (OVID)
RI
Regulus Therapeutics Inc.
Director
2012 – 2025 · Public company (RGLS)
BI
Biogen Inc.
Director
2008 – 2022 · Public company (BIIB)
EC
Eucrates Biomedical Acquisition Corp.
Director and 10% owner
2020 · Public company (EUCR)
BI
BG Medicine, Inc.
Director
2011 – 2015 · Public company (BGMD)
AI
Anadys Pharmaceuticals Inc.
Director
2006 – 2011 · Public company (ANDS)
GI
Genvec Inc.
Director
2006 · Public company (GNVC)
SI
SGX Pharmaceuticals, Inc.
Director
2006 · Public company (SGXP)
Key Colleagues at Startups
The people Stelios Papadopoulos works with at each company, as listed on that company's latest Form D.
Epikast Inc. · Form D, Feb 5, 2026
BP
Brad Prosek
Director
EV
Evangelos Vergetis
President and director
ON
Oleg Nodelman
Director
DK
Daphne Karydas
Director
AT
Alexandros Tzoukas
Director
DP
Dimitrios Papalexopoulos
Director